Literature DB >> 11295427

In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT.

M Kassiou1, S Eberl, S R Meikle, A Birrell, C Constable, M J Fulham, D F Wong, J L Musachio.   

Abstract

To quantify changes in neuronal nAChR binding in vivo, quantitative dynamic SPECT studies were performed with 5-[(123)I]-iodo-A-85380 in baboons pre and post chronic treatment with (-)-nicotine or saline control. Infusion of (-)-nicotine at a dose of 2.0 mg/kg/24h for 14 days resulted in plasma (-)-nicotine levels of 27.3 ng/mL. This is equivalent to that found in an average human smoker (20 cigarettes a day). In the baboon brain the regional distribution of 5-[(123)I]-iodo-A-85380 was consistent with the known densities of nAChRs (thalamus > frontal cortex > cerebellum). Changes in nAChR binding were estimated from the volume of distribution (V(d) ) and binding potential (BP) derived from 3-compartment model fits. In the (-)-nicotine treated animal V(d) was significantly increased in the thalamus (52%) and cerebellum (50%) seven days post cessation of (-)-nicotine treatment, suggesting upregulation of nAChRs. The observed 33% increase in the frontal cortex failed to reach significance. A significant increase in BP was seen in the thalamus. In the saline control animal no changes were observed in V(d) or BP under any experimental conditions. In this preliminary study, we have demonstrated for the first time in vivo upregulation of neuronal nAChR binding following chronic (-)-nicotine treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295427     DOI: 10.1016/s0969-8051(00)00206-7

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  10 in total

1.  Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.

Authors:  L Eugene Arnold; Michael G Aman; Jill Hollway; Elizabeth Hurt; Bethany Bates; Xiaobai Li; Cristan Farmer; Rene Anand; Susan Thompson; Yaser Ramadan; Craig Williams
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

2.  Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline.

Authors:  Jill R Turner; Laura M Castellano; Julie A Blendy
Journal:  Nicotine Tob Res       Date:  2010-11-22       Impact factor: 4.244

3.  Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.

Authors:  G Patrick Hussmann; Jill R Turner; Ermelinda Lomazzo; Rashmi Venkatesh; Vanessa Cousins; Yingxian Xiao; Robert P Yasuda; Barry B Wolfe; David C Perry; Amir H Rezvani; Edward D Levin; Julie A Blendy; Kenneth J Kellar
Journal:  J Pharmacol Exp Ther       Date:  2012-08-16       Impact factor: 4.030

4.  Effects of continuous nicotine treatment and subsequent termination on cocaine versus food choice in male rhesus monkeys.

Authors:  Kathryn L Schwienteck; S Stevens Negus; Justin L Poklis; Matthew L Banks
Journal:  Exp Clin Psychopharmacol       Date:  2015-06-22       Impact factor: 3.157

5.  Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Authors:  James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong
Journal:  Synapse       Date:  2009-04       Impact factor: 2.562

6.  Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task.

Authors:  Daniel Scott; Jane R Taylor
Journal:  Behav Brain Res       Date:  2013-11-14       Impact factor: 3.332

Review 7.  Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies.

Authors:  Steven J Simmons; Thomas J Gould
Journal:  J Clin Pharm Ther       Date:  2014-05-14       Impact factor: 2.512

Review 8.  Guidelines on nicotine dose selection for in vivo research.

Authors:  Shannon G Matta; David J Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward D Levin; Ronald J Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

Review 9.  The possible contribution of neuronal nicotinic acetylcholine receptors in depression.

Authors:  Daniel Bertrand
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

10.  Effect of traumatic brain injury on nicotine-induced modulation of dopamine release in the striatum and nucleus accumbens shell.

Authors:  Yuan-Hao Chen; Tung-Tai Kuo; Eagle Yi-Kung Huang; Yu-Ching Chou; Yung-Hsiao Chiang; Barry J Hoffer; Jonathon Miller
Journal:  Oncotarget       Date:  2018-01-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.